Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.
Read the FSRH CEU Clinical guidance workplan for 2021/2022.
The Clinical Effectiveness Unit have had a number of recent queries around the extended use of LARC during COVID19. We would like to remind Members that extended use of LARC was recommended only when health risk associated with COVID19 transmission was at its highest.
Read and download the job description here.
Download the FSRH's AGM unconfirmed minutes - 21 October 2021.
FSRH-RCOG submission to the NI Assembly consultation on the Abortion Services (Safe Access Zones) Bill.
Benilexa® (Gedeon Richter) - a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) with a reloadable one-handed insertion device - is now available in the UK. Benilexa is licensed for 6 years of use for contraception. It is not licensed for endometrial protection as part of HRT. This FSRH CEU Resource provides a table which compares the product characteristics of LNG-IUS devices currently available in the UK, Benilexa®, Levosert®, Mirena®, Kyleena® and Jaydess®.
Information on Mentoring Discussion Groups for mentors, including upcoming dates.
List of Menopause Care SSM Principal Trainers
Download a full list of mentoring representatives here.
A summary of the APPG SRH's event 'Investing in Women's Lives', focused on the importance of a lifecourse approach to sexual and reproductive healthcare - held on 26th October 2021.
